Cargando empresa
LLYELI Lilly And Company1,36T US$A+Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
Estados financieros completos →
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
Construido a partir de los propios informes de Astrazeneca plc ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
184,49 US$+0,1 %cierre 13 nov
Cifras hasta el 30 de septiembre de 2026, del 6-K presentado el 30 de octubre de 2026
AstraZeneca sells prescription medicines for cancer, heart and kidney disease, lung conditions and rare disorders to patients through healthcare systems worldwide.
Grade B+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 26 trimestres del historial de calificaciones de Astrazeneca plc. Los otros 24 llegan hasta marzo de 2018.
